Post-Traumatic Stress Disorder – Executive Insights – Executive Insights – Post-Traumatic Stress Disorder (US)
Post-traumatic stress disorder (PTSD) is a chronic psychiatric condition that may emerge after a person experiences a traumatic event or series of events. Multiple guidelines recommend first treating PTSD with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of pharmacological agents. Pharmacological options for PTSD are limited, with only two FDA-approved agents, paroxetine and sertraline. Other agents, such as SNRIs, mood stabilizers, and atypical antipsychotics, may be used off-label, despite limited evidence of efficacy. Additional treatment options are in late-phase development. Lykos Therapeutics’ MDMA-assisted psychotherapy has undergone Phase 3 trials in moderate to severe PTSD patients and is under FDA review as of June 2024. Otsuka and Lundbeck have submitted Rexulti (used in combination with sertraline) for FDA approval for PTSD; they had previously reported positive results in one Phase 2 and one Phase 3 trial. These and other pipeline agents offer the potential for more-efficacious PTSD management.
Questions answered:
- What is the prevalence of PTSD in the United States?
- What is the treatment journey of PTSD patients?
- What is the competitive landscape and the expected future influence of key emerging therapies, including MDMA-assisted psychotherapy and Rexulti, in PTSD?
- What are the strengths, weaknesses, drivers, and constraints of the PTSD market?
- What are the key areas of unmet need and opportunities in the management of PTSD patients, according to KOLs?
Product description:
Executive Insights provides indication-specific market intelligence withworld-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Release date: June 2024
Geography: United States
Primary Research: 3 KOL interviews in February 2024
Key companies covered: Lykos Therapeutics, Otsuka Pharmaceutical, Lundbeck, Boehringer Ingelheim, Alto Neuroscience, Compass Pathways, Bionomics
Key drugs covered: SSRIs, SNRIs, atypical antipsychotics, mood stabilizers, beta blockers, benzodiazepines
